Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy

J Am Heart Assoc. 2022 May 3;11(9):e024566. doi: 10.1161/JAHA.121.024566. Epub 2022 May 3.
No abstract available

Keywords: drug treatment; hypertrophic cardiomyopathy; mavacamten; surgical myectomy.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Cardiomyopathy, Hypertrophic* / surgery
  • Cardiovascular Agents*
  • Heart Septum / surgery
  • Humans

Substances

  • Cardiovascular Agents